FY2025 EPS Estimate for Solid Biosciences Lowered by Analyst

Solid Biosciences Inc. (NASDAQ:SLDB - Free Report) - Research analysts at Cantor Fitzgerald cut their FY2025 EPS estimates for shares of Solid Biosciences in a note issued to investors on Thursday, May 22nd. Cantor Fitzgerald analyst K. Kluska now anticipates that the company will post earnings per share of ($2.06) for the year, down from their prior forecast of ($1.60). Cantor Fitzgerald currently has a "Overweight" rating and a $16.00 price objective on the stock. The consensus estimate for Solid Biosciences' current full-year earnings is ($2.84) per share.

Solid Biosciences (NASDAQ:SLDB - Get Free Report) last issued its earnings results on Thursday, May 15th. The company reported ($0.59) EPS for the quarter, missing analysts' consensus estimates of ($0.53) by ($0.06).

A number of other analysts have also recently issued reports on the stock. Barclays reduced their target price on shares of Solid Biosciences from $15.00 to $10.00 and set an "overweight" rating for the company in a research note on Friday, May 16th. Wedbush cut their price target on shares of Solid Biosciences from $18.00 to $17.00 and set an "outperform" rating on the stock in a report on Friday, May 16th. Piper Sandler decreased their price objective on shares of Solid Biosciences from $20.00 to $17.00 and set an "overweight" rating for the company in a report on Friday, May 16th. JPMorgan Chase & Co. lowered their target price on shares of Solid Biosciences from $12.00 to $11.00 and set an "overweight" rating on the stock in a research report on Thursday, March 13th. Finally, Chardan Capital cut their target price on Solid Biosciences from $16.00 to $15.00 and set a "buy" rating on the stock in a report on Monday, May 19th. Ten analysts have rated the stock with a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Buy" and an average price target of $14.90.

Solid Biosciences Stock Performance

Shares of Solid Biosciences stock traded down $0.16 during trading on Monday, hitting $3.15. 92,828 shares of the stock traded hands, compared to its average volume of 1,078,574. The stock has a market cap of $243.78 million, a P/E ratio of -1.03 and a beta of 2.32. The company has a fifty day moving average price of $3.15 and a two-hundred day moving average price of $4.04. Solid Biosciences has a twelve month low of $2.41 and a twelve month high of $10.37.

Institutional Trading of Solid Biosciences

Several hedge funds have recently added to or reduced their stakes in the business. CWM LLC boosted its position in shares of Solid Biosciences by 15,188.5% in the first quarter. CWM LLC now owns 7,950 shares of the company's stock valued at $29,000 after acquiring an additional 7,898 shares during the period. China Universal Asset Management Co. Ltd. acquired a new position in Solid Biosciences during the 4th quarter valued at $34,000. Corton Capital Inc. bought a new stake in Solid Biosciences in the 4th quarter valued at $41,000. Ground Swell Capital LLC acquired a new stake in Solid Biosciences in the 1st quarter worth $42,000. Finally, Invesco Ltd. acquired a new stake in Solid Biosciences in the 4th quarter worth $49,000. Institutional investors own 81.46% of the company's stock.

Solid Biosciences Company Profile

Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.